Vantictumab (Anti-FZD)Vantictumab (Anti-FZD)
Move your mouse over image or click to enlarge

Vantictumab (Anti-FZD)

Vantictumab (Anti-FZD) is a monoclonal antibody targeting the Wnt signaling pathway with potential antineoplastic activity. Vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This results in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. MW: 145.5 KD.
Cat# Size Price Qty Buy
A2489-1mg*25 1mg*25
£4,152.00
A2489-1mg*5 1mg*5
£1,384.00
A2489-1mg 1mg
£441.00

Additional Information

Property Value or Rating
Manufacturer Selleck Chemicals LLC
Manufacturer Cat# A2489

Related Documents